Literature DB >> 20086087

Yersinia pestis with regulated delayed attenuation as a vaccine candidate to induce protective immunity against plague.

Wei Sun1, Kenneth L Roland, Xiaoying Kuang, Christine G Branger, Roy Curtiss.   

Abstract

Two mutant strains of Yersinia pestis KIM5+, a Deltacrp mutant and a mutant with arabinose-dependent regulated delayed-shutoff crp expression (araC P(BAD) crp), were constructed, characterized in vitro, and evaluated for virulence, immunogenicity, and protective efficacy in mice. Both strains were highly attenuated by the subcutaneous (s.c.) route. The 50% lethal doses (LD(50)s) of the Deltacrp and araC P(BAD) crp mutants were approximately 1,000,000-fold and 10,000-fold higher than those of Y. pestis KIM5+, respectively, indicating that both strains were highly attenuated. Mice vaccinated s.c. with 3.8 x 10(7) CFU of the Deltacrp mutant developed high anti-Y. pestis and anti-LcrV serum IgG titers, both with a strong Th2 bias, and induced protective immunity against subcutaneous challenge with virulent Y. pestis (80% survival) but no protection against pulmonary challenge. Mice vaccinated with 3.0 x 10(4) CFU of the araC P(BAD) crp mutant also developed high anti-Y. pestis and anti-LcrV serum IgG titers but with a more balanced Th1/Th2 response. This strain induced complete protection against s.c. challenge and partial protection (70% survival) against pulmonary challenge. Our results demonstrate that arabinose-dependent regulated crp expression is an effective strategy to attenuate Y. pestis while retaining strong immunogenicity, leading to protection against the pneumonic and bubonic forms of plague.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20086087      PMCID: PMC2825917          DOI: 10.1128/IAI.01122-09

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  51 in total

1.  Design and testing for a nontagged F1-V fusion protein as vaccine antigen against bubonic and pneumonic plague.

Authors:  Bradford S Powell; Gerard P Andrews; Jeffrey T Enama; Scott Jendrek; Chris Bolt; Patricia Worsham; Jeffrey K Pullen; Wilson Ribot; Harry Hines; Leonard Smith; David G Heath; Jeffrey J Adamovicz
Journal:  Biotechnol Prog       Date:  2005 Sep-Oct

2.  Cyclic AMP and its receptor protein negatively regulate the coordinate expression of cholera toxin and toxin-coregulated pilus in Vibrio cholerae.

Authors:  K Skorupski; R K Taylor
Journal:  Proc Natl Acad Sci U S A       Date:  1997-01-07       Impact factor: 11.205

3.  Salmonella SirA is a global regulator of genes mediating enteropathogenesis.

Authors:  B M Ahmer; J van Reeuwijk; P R Watson; T S Wallis; F Heffron
Journal:  Mol Microbiol       Date:  1999-02       Impact factor: 3.501

4.  Resistance to lipopolysaccharide mediated by the Yersinia pestis V antigen-polyhistidine fusion peptide: amplification of interleukin-10.

Authors:  Y A Nedialkov; V L Motin; R R Brubaker
Journal:  Infect Immun       Date:  1997-04       Impact factor: 3.441

5.  Cell-mediated protection against pulmonary Yersinia pestis infection.

Authors:  Michelle A Parent; Kiera N Berggren; Lawrence W Kummer; Lindsey B Wilhelm; Frank M Szaba; Isis K Mullarky; Stephen T Smiley
Journal:  Infect Immun       Date:  2005-11       Impact factor: 3.441

6.  Transcriptional activation of Salmonella typhimurium invasion genes by a member of the phosphorylated response-regulator superfamily.

Authors:  C Johnston; D A Pegues; C J Hueck; A Lee; S I Miller
Journal:  Mol Microbiol       Date:  1996-11       Impact factor: 3.501

7.  The spv virulence operon of Salmonella typhimurium LT2 is regulated negatively by the cyclic AMP (cAMP)-cAMP receptor protein system.

Authors:  C P O'Byrne; C J Dorman
Journal:  J Bacteriol       Date:  1994-02       Impact factor: 3.490

Review 8.  The virulence plasmid of Yersinia, an antihost genome.

Authors:  G R Cornelis; A Boland; A P Boyd; C Geuijen; M Iriarte; C Neyt; M P Sory; I Stainier
Journal:  Microbiol Mol Biol Rev       Date:  1998-12       Impact factor: 11.056

9.  Passive immunity to yersiniae mediated by anti-recombinant V antigen and protein A-V antigen fusion peptide.

Authors:  V L Motin; R Nakajima; G B Smirnov; R R Brubaker
Journal:  Infect Immun       Date:  1994-10       Impact factor: 3.441

10.  DNA sequencing and analysis of the low-Ca2+-response plasmid pCD1 of Yersinia pestis KIM5.

Authors:  R D Perry; S C Straley; J D Fetherston; D J Rose; J Gregor; F R Blattner
Journal:  Infect Immun       Date:  1998-10       Impact factor: 3.441

View more
  18 in total

Review 1.  Developing live vaccines against plague.

Authors:  Wei Sun; Kenneth L Roland; Roy Curtiss
Journal:  J Infect Dev Ctries       Date:  2011-09-14       Impact factor: 0.968

2.  Oral administration of a recombinant attenuated Yersinia pseudotuberculosis strain elicits protective immunity against plague.

Authors:  Wei Sun; Shilpa Sanapala; Hannah Rahav; Roy Curtiss
Journal:  Vaccine       Date:  2015-10-26       Impact factor: 3.641

3.  LcrV delivered via type III secretion system of live attenuated Yersinia pseudotuberculosis enhances immunogenicity against pneumonic plague.

Authors:  Wei Sun; Shilpa Sanapala; Jeremy C Henderson; Shandiin Sam; Joseph Olinzock; M Stephen Trent; Roy Curtiss
Journal:  Infect Immun       Date:  2014-08-11       Impact factor: 3.441

4.  Fine-tuning synthesis of Yersinia pestis LcrV from runaway-like replication balanced-lethal plasmid in a Salmonella enterica serovar typhimurium vaccine induces protection against a lethal Y. pestis challenge in mice.

Authors:  Ascención Torres-Escobar; María Dolores Juárez-Rodríguez; Bronwyn M Gunn; Christine G Branger; Steven A Tinge; Roy Curtiss
Journal:  Infect Immun       Date:  2010-03-22       Impact factor: 3.441

5.  A live attenuated strain of Yersinia pestis KIM as a vaccine against plague.

Authors:  Wei Sun; David Six; Xiaoying Kuang; Kenneth L Roland; Christian R H Raetz; Roy Curtiss
Journal:  Vaccine       Date:  2011-02-12       Impact factor: 3.641

6.  Biosafety level 2 model of pneumonic plague and protection studies with F1 and Psa.

Authors:  Estela M Galván; Manoj Kumar Mohan Nair; Huaiqing Chen; Fabio Del Piero; Dieter M Schifferli
Journal:  Infect Immun       Date:  2010-05-24       Impact factor: 3.441

Review 7.  Plague Vaccines: Status and Future.

Authors:  Wei Sun
Journal:  Adv Exp Med Biol       Date:  2016       Impact factor: 2.622

8.  Evaluation of regulated delayed attenuation strategies for Salmonella enterica serovar Typhi vaccine vectors in neonatal and infant mice.

Authors:  Huoying Shi; Shifeng Wang; Roy Curtiss
Journal:  Clin Vaccine Immunol       Date:  2013-04-24

9.  Functional characterization of Yersinia pestis aerobic glycerol metabolism.

Authors:  Stephan P Willias; Sadhana Chauhan; Vladimir L Motin
Journal:  Microb Pathog       Date:  2014-09-16       Impact factor: 3.738

Review 10.  Rational considerations about development of live attenuated Yersinia pestis vaccines.

Authors:  Wei Sun; Roy Curtiss
Journal:  Curr Pharm Biotechnol       Date:  2013       Impact factor: 2.837

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.